Fertility and Sterility
Volume 82, Issue 1 , Pages 119-125 , July 2004

Luteinizing hormone concentrations after gonadotropin-releasing hormone antagonist administration do not influence pregnancy rates in in vitro fertilization–embryo transfer

  • Philippe Merviel, M.D., Ph.D.

      Affiliations

    • Department of Gynecology, Obstetrics and Reproductive Medicine, Hǒpital Tenon, Paris, France
    • Corresponding Author InformationReprint requests: Philippe Merviel, M.D., Ph.D., Department of Gynecology, Obstetrics and Reproductive Medicine, Hǒpital Tenon, 4 rue de la Chine, 75020 Paris, France (FAX: 00-33-01-56-01-60-62).
    • ,
  • Jean-Marie Antoine, M.D., Ph.D.

      Affiliations

    • Department of Gynecology, Obstetrics and Reproductive Medicine, Hǒpital Tenon, Paris, France
    • ,
  • Emmanuelle Mathieu, M.D.

      Affiliations

    • Department of Gynecology, Obstetrics and Reproductive Medicine, Hǒpital Tenon, Paris, France
    • ,
  • Françoise Millot, M.D.

      Affiliations

    • Laboratory of Biochemistry, Hǒpital Tenon, Paris, France
    • ,
  • Jacqueline Mandelbaum, M.D.

      Affiliations

    • Laboratory of In Vitro Fertilization and Cytogenetics, Hǒpital Tenon, Paris, France
    • ,
  • Serge Uzan, M.D., Ph.D.

      Affiliations

    • Department of Gynecology, Obstetrics and Reproductive Medicine, Hǒpital Tenon, Paris, France

Received 14 May 2003 ,Revised 10 November 2003 ,Accepted 10 November 2003.

References 

  1. Knobil E. The neuroendocrine control of the menstrual cycle. Recent Prog Horm Res. 1980;36:53–88
  2. Hillier SG, Tetsuka M, Fraser HM. Location and developmental regulation of androgen receptor in primate ovary. Hum Reprod. 1997;12:107–111
  3. Levy D, Navarro JM, Schattman GL, Davis OK, Rosenwaks Z. The role of LH in ovarian stimulation. Exogenous LH (let's design the future). Hum Reprod. 2000;15:2258–2265
  4. Sullivan MW, Stewart-Akers A, Krasnow JS, Berga SL, Zeleznik AJ. Ovarian responses in women to recombinant follicle-stimulating hormone and luteinizing hormone (LH) (a role for LH in the final stages of follicular maturation). J Clin Endocrinol Metab. 1999;84:228–232
  5. Fleming R, Chung CC, Yates RWS, Coutts JR. Purified urinary follicle stimulating hormone induces different hormone profiles compared with menotrophins, dependent upon the route of administration and endogenous luteinizing hormone activity. Hum Reprod. 1996;11:1854–1858
  6. Agrawal R, Conway GS, Engmann L. Implications of using follicle-stimulating hormone preparations depleted of luteinizing hormone to achieve follicular growth in in vitro fertilization. Gynecol Endocrinol. 1998;12:9–15
  7. Schoot DC, Harlin J, Shoham Z, Mannaerts BM, Lahlou N, Bouchard P, et al.  Recombinant follicle-stimulating hormone and ovarian response in gonadotropin-deficient women. Hum Reprod. 1994;9:1237–1242
  8. Filicori M. The role of luteinizing hormone in folliculogenesis and ovulation induction. Fertil Steril. 1999;71:405–414
  9. Karten MJ, Rivier JE. Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists (rationale and perspective). Endocrinol Rev. 1986;7:44–66
  10. Reissmann T, Felberbaum R, Diedrich K, Engel J, Comaru-Schally AM, Schally AV. Development and applications of luteinizing hormone–releasing hormone antagonists in the treatment of infertility (an overview). Hum Reprod. 1995;10:1974–1981
  11. Diedrich K, Diedrich C, Santos E, Zoll C, al Hassani S, Reissmann T, et al.  Suppression of the endogenous luteinizing hormone surge by gonadotrophin-releasing hormone antagonist cetrorelix during ovarian stimulation. Hum Reprod. 1994;9:788–791
  12. Felberbaum RE, Reissmann T, Küpker W, Bauer O, al Hassani S, Diedrich C, et al.  Preserved pituitary response under ovarian stimulation with human menopausal gonadotropin (HMG) and concomitant administration of the gonadotropin releasing hormone (GnRH)-antagonist Cetrorelix in women with tubal infertility. Eur J Obstet Gynecol Reprod Biol. 1995;61:151–155
  13. The European Orgalutran Study Group, Borm G, Mannaerts B . Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient (results of a controlled, randomized, multicentre trial). Hum Reprod. 2000;15:1490–1498
  14. Shoham Z, Balen A, Patel A. Results of ovulation induction using human menopausal gonadotropin or purified follicle-stimulating hormone in hypogonadotropic hypogonadism patients. Fertil Steril. 1991;56:1048–1053
  15. Balasch J, Miro F, Burzaco I. The role of luteinizing hormone in human follicle development and oocyte fertility (evidence from in vitro fertlization in a woman with long-standing hypogonadotrophic hypogonadism and using recombinant human follicle stimulating hormone). Hum Reprod. 1995;10:1678–1683
  16. Fleming R, Lloyd F, Herbert M, Fenwick J, Griffiths T, Murdoch A. Effects of profound suppression of luteinizing hormone during ovarian stimulation on follicular activity, oocyte and embryo function in cycles stimulated with purified follicle stimulating hormone. Hum Reprod. 1998;13:1788–1792
  17. Antoine JM, Salat-Baroux J, Alvarez S, Cornet D, Tibi C, Mandelbaum J, et al.  Ovarian stimulation using human menopausal gonadotrophins with or without LHRH analogues in a long protocol for in-vitro fertilization (a prospective randomized comparison). Hum Reprod. 1990;5:565–569
  18. Mandelbaum J, Belaisch-Allart J, Junca AM, Antoine JM, Plachot M, Alvarez S, et al.  Cryopreservation in human assisted reproduction is now routine for embryos but remains a research procedure for oocytes. Hum Reprod. 1998;13:161–174
  19. Gougeon A. Dynamics of follicular growth in the human (a model from preliminary results). Hum Reprod. 1986;1:81–87
  20. Adashi EY. The ovarian follicular apparatus. In:  Adashi EY,  Rock JA,  Rosenwaks Z editor. Reproductive endocrinology, surgery, and technology. Philadelphia: Lippincott-Raven; 1996;p. 17–40
  21. Erickson GF, Wang C, Hsueh M. FSH induction of functional LH receptors in granulosa cells cultured in a chemically defined medium. Nature. 1979;279:336–338
  22. Gordon UD. Effects of different menotropin preparations for assisted reproduction in hypogonadotropic hypogonadism. In:  Filicori M editors. The role of luteinizing hormone in folliculogenesis and ovulation induction. Bologna: Monduzzi Editore; 1999;p. 135–143
  23. Hull ML, Livesey JH, Evans JJ, Benny PS. The effect of recombinant follicle stimulating hormone (Gonal-F) on endogenous luteinizing hormone secretion in women. Hum Reprod. 1998;13:1139–1143
  24. The Ganirelix Dose-Finding Study Group . A double-bind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). Hum Reprod. 1998;13:3023–3031
  25. Albano C, Smitz J, Camus M, Riethmüller-Winzen H, Van Steirteghem A, Devroey P. Comparison of different doses of gonadotropin-releasing hormone anatgonist Cetrorelix during controlled ovarian hyperstimulation. Fertil Steril. 1997;67:917–922
  26. Minaretzis D, Alper MM, Oskowitz SP, Lobel SM, Mortola JF, Pavlou SN. Gonadotropin-releasing hormone antagonist versus agonist administration in women undergoing controlled ovarian hypertsimulation (cycle performance and in vitro steroidogenesis of granulosa-lutein cells). Am J Obstet Gynecol. 1995;172:1518–1525
  27. Westergaard LG, Laursen SB, Yding Andersen C. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normo-gonadotrophic women undergoing assisted reproduction. Hum Reprod. 2000;15:1003–1008
  28. Short RV. The synthesis and secretion of steroids by the corpus luteum. Arch Anat Morphol Exp Microsc. 1967;56:258–272
  29. Yding Andersen C. Characteristics of human follicular fluid associated with successful conception after in vitro fertilization. J Clin Endocrin Metab. 1993;77:1227–1234
  30. Yoshimura Y, Wallach EE. Studies on the mechanism(s) of mammalian ovulation. Fertil Steril. 1987;47:22–34
  31. Tesarik J, Mendoza C. Nongenomic effects of 17 beta-estradiol on maturating human oocytes (relationship to oocyte developmental potential). J Clin Endocrinol Metab. 1995;80:1438–1443
  32. Loumaye E, Engrand P, Howles C, O'Dea L. Assessment of the role of serum luteinizing hormone and estradiol response to follicle-stimulating hormone on in vitro fertilization treatment outcome. Fertil Steril. 1997;67:889–899
  33. Kelly EE, Nebiolo L. Recombinant FSH therapy alone (Gonal-F) versus combination therapy (Gonal-F + Lhadi, R-HLH) in patients down-regulated with low dose luteal GnRH agonist protocol. Preliminary results. In: Proceedings of the 11th World Congress on In Vitro Fertilization and Human Reproductive Genetics, 1999. Abstract S-003
  34. Chappel S, Howles C. Reevaluation of the roles of luteinizing hormone and follicle stimulating hormone in the ovulatory process. Hum Reprod. 1991;6:1206–1212
  35. The European Recombinant Human LH Study Group . Recombinant human luteinizing hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-induced follicular development in LH- and FSH-deficient anovulatory women (a dose-finding study). J Clin Endocrinol Metab. 1998;83:1507–1514
  36. Olivennes F, Fanchin R, Bouchard P, Taieb J, Selva J, Frydman R. Scheduled administration of a LH-RH antagonist (cetrorelix) on day 8 of in vitro fertilization cycles (a pilot study). Hum Reprod. 1995;10:1382–1386
  37. Olivennes F, Alvarez S, Bouchard P, Fanchin R, Salat-Baroux J, Frydman R. The use of a LH-RH antagonist (cetrorelix) in a single dose protocol in in vitro fertilization and embryo transfer (a dose finding study of 3 versus 2 mg). Hum Reprod. 1998;13:2411–2414
  38. Klingmüller D, Schepke M, Enzweiler C, Bidlingmaier F. Hormonal response to the new potent GnRH-antagonist Cetrorelix. Acta Endocrinol. 1993;128:15–18
  39. Gordon K, Williams RF, Danforth DR, Hodgen GD. A novel regimen of gonadotropin-releasing hormone (GnRH) antagonist plus pulsatile GnRH (controlled restoration of gonadotropin secretion and ovulation induction). Fertil Steril. 1990;54:1140–1145

PII: S0015-0282(04)00529-1

doi: 10.1016/j.fertnstert.2003.11.040

Fertility and Sterility
Volume 82, Issue 1 , Pages 119-125 , July 2004

Article Tools